Literature DB >> 35400000

Monostotic Fibrous Dysplasia in the Femur Strongly Expressing RANKL With Concomitant Osteoporotic Vertebral Compression Fracture: A Case Report.

Edelyn S Azurin1,2, Norio Yamamoto1, Katsuhiro Hayashi1, Akihiko Takeuchi1, Shinji Miwa1, Kentaro Igarashi1, Takashi Higuchi1, Hirotaka Yonezawa1, Sei Morinaga1, Yohei Asano1, Shiro Saito1, Hiroyuki Tsuchiya1.   

Abstract

Background/Aim: This study aimed to present a rare case of fibrous dysplasia (FD) in a healthy young adult man with a concomitant osteoporotic vertebral compression fracture. FD is a benign lesion of the bone characterized by replacement of the medullary component with fibro-osseous tissue that contains abnormally arranged trabeculae of immature woven bone. Recently it has been reported that several bone tumors including FD express the receptor activator of nuclear factor-kappa B (RANK) and its ligand (RANKL). Therefore, we hypothesized that FD contributed to osteoporosis, linked by the RANK-RANKL pathway of osteoclastogenesis. Case Report: We report the case of a healthy man with monostotic femoral fibrous dysplasia (FD) with concomitant 7 th thoracic vertebra compression fracture due to osteoporosis [young adult mean (YAM) was 79% in bone mineral density (BMD)]. After curettage of the FD, artificial bone grafting in the cavity, and administration of alendronate sodium, BMD improved considerably within 9 months. FD is a benign bone condition in which abnormal fibrous tissue replaces normal bone. The axis of the receptor activator of nuclear factor-kappa B (RANK) and its ligand (RANKL) has been implicated in osteoporosis pathogenesis. RANKL immunohistochemical staining was performed, and strong staining of stromal cells was observed compared to other FD cases that showed weak to moderate staining.
Conclusion: The presence of FD might have contributed to the low BMD due to the RANK-RANKL axis acting as osteoclastogenesis stimulator. Copyright 2022, International Institute of Anticancer Research.

Entities:  

Keywords:  Fibrous dysplasia; alendronate sodium; bone mineral density; osteoporosis; receptor activator of nuclear factor-kappa B ligand (RANKL); receptor activator of nuclear factorkappa B (RANK); vertebral fracture

Year:  2022        PMID: 35400000      PMCID: PMC8962839          DOI: 10.21873/cdp.10082

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  15 in total

Review 1.  FDG PET/CT of primary bone tumors.

Authors:  Colleen M Costelloe; Hubert H Chuang; John E Madewell
Journal:  AJR Am J Roentgenol       Date:  2014-06       Impact factor: 3.959

2.  Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.

Authors:  Luis F de Castro; Andrea B Burke; Howard D Wang; Jeffrey Tsai; Pablo Florenzano; Kristen S Pan; Nisan Bhattacharyya; Alison M Boyce; Rachel I Gafni; Alfredo A Molinolo; Pamela G Robey; Michael T Collins
Journal:  J Bone Miner Res       Date:  2018-11-29       Impact factor: 6.741

3.  INSM1 Is More Sensitive and Interpretable than Conventional Immunohistochemical Stains Used to Diagnose Merkel Cell Carcinoma.

Authors:  Mohammed T Lilo; Youdinghuan Chen; Robert E LeBlanc
Journal:  Am J Surg Pathol       Date:  2018-11       Impact factor: 6.394

4.  Current approach to fibrous dysplasia of bone and McCune-Albright syndrome.

Authors:  Arabella I Leet; Michael T Collins
Journal:  J Child Orthop       Date:  2007-02-23       Impact factor: 1.548

5.  RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.

Authors:  Biagio Palmisano; Emanuela Spica; Cristina Remoli; Rossella Labella; Annamaria Di Filippo; Samantha Donsante; Fabiano Bini; Domenico Raimondo; Franco Marinozzi; Alan Boyde; Pamela Robey; Alessandro Corsi; Mara Riminucci
Journal:  J Bone Miner Res       Date:  2019-08-21       Impact factor: 6.390

Review 6.  The clinical epidemiology of male osteoporosis: a review of the recent literature.

Authors:  Tina Willson; Scott D Nelson; Jonathan Newbold; Richard E Nelson; Joanne LaFleur
Journal:  Clin Epidemiol       Date:  2015-01-09       Impact factor: 4.790

7.  Fibrous dysplasia: an overview of disease process, indications for surgical management, and a case report.

Authors:  Oluwaseun A Adetayo; Samuel E Salcedo; Vedant Borad; Sara S Richards; Adrienne D Workman; Andrea O Ray
Journal:  Eplasty       Date:  2015-02-26

8.  Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.

Authors:  Tetsuro Yamagishi; Hiroyuki Kawashima; Akira Ogose; Takashi Ariizumi; Taro Sasaki; Hiroshi Hatano; Tetsuo Hotta; Naoto Endo
Journal:  PLoS One       Date:  2016-05-10       Impact factor: 3.240

9.  Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary.

Authors:  Hajime Orimo; Toshitaka Nakamura; Takayuki Hosoi; Masayuki Iki; Kazuhiro Uenishi; Naoto Endo; Hiroaki Ohta; Masataka Shiraki; Toshitsugu Sugimoto; Takao Suzuki; Satoshi Soen; Yoshiki Nishizawa; Hiroshi Hagino; Masao Fukunaga; Saeko Fujiwara
Journal:  Arch Osteoporos       Date:  2012       Impact factor: 2.617

10.  Alendronate sodium in the management of osteoporosis.

Authors:  P J J Prinsloo; D J Hosking
Journal:  Ther Clin Risk Manag       Date:  2006-09       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.